Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

ARCAGY/ GINECO GROUP130 enrolled

Overview

This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

Relapsed Ovarian Cancers Patients

Interventions

OlaparibDRUG

Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be female ≥18 years of age * Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy * Patients can be either alive or deceased at the time of medical record abstraction * Patients should not have any objection that anonymized data will be collected and subjected to automated processing. Exclusion Criteria: * Patient that were given olaparib within a clinical trial

Locations (28)

ICO Paul Papin

Angers, France

Outcomes

Primary Outcomes

progression free survival (PFS)

PFS (days) = date of progression - date of treatment start + 1

Time frame: through study completion, an average of 1 year

overall Survival (OS)

OS (days) = date of death - date of treatment start + 1

Time frame: through study completion, an average of 1 year

incidence of events of clinical interest

the following events: anemia, thrombopenia, nausea and vomiting, fatigue, myelodysplastic syndrome, upper respiratory infections, diarrhea, decreased appetite, dysgeusia and headache will be formally retrieved from the source documents.

Time frame: through study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.